Previous 10 | Next 10 |
OraSure Technologies ([[OSUR]] +5.2%) announces that its OMNIgene·ORAL (OM-505) saliva collection kit was included in the Emergency Use Authorization ((EUA)) granted to Ambry Genetics for use in its Ambry COVID-19 RT-PCR saliva test.OMNIgene·ORAL, which is a product of sub...
BETHLEHEM, Pa., Jan. 29, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its OMNIgene®·ORAL (OM-505) saliva collection ki...
OraSure Technologies' (OSUR) OMNIgene ORAL (OME-505) saliva collection device, a product of Ottawa-based subsidiary DNA Genotek, has received authorization from Health Canada for use as a component in molecular diagnostic tests for the detection of SARS-CoV-2.Diagnostic labs, provincial and t...
OTTAWA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its OMNIgene ® ·ORAL (OME-505) saliva collection dev...
BETHLEHEM, Pa., Jan. 26, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Chronomics Limited has selected the OMNIgene®...
ST. PAUL, Minn., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ: OSUR), today announced that Eric Pamer, M.D., Professor of Medicine, Section of Infectious Diseases and Global Health and director of the Duchossois Family Institute at th...
OraSure Technologies (OSUR) announces that its OragenDx (OGD-610) saliva collection device was included as a component in the De Novo authorization granted by the FDA to Helix for their Helix Laboratory Platform, a whole exome sequencing platform.This is the first exome sequencing-based ...
BETHLEHEM, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Oragene ® •Dx (OGD-610) saliva co...
GenMark is in the early stages of an accelerated growth phase, backed by the cadence of ePlex instillations, having benefitted from a large Covid-19 tailwind. Management are solid on scaling production to 250K ePlex units by Q3 2021 and are aiming to reach 60% gross profit margins ove...
OraSure is well positioned to capture additional market share in DNA at-home testing and molecular collection device sales. The company offers differentiated propositions with unique exposure to the genome, microbiome and Covid-19 testing. Sequential growth patterns quarter/quarte...
News, Short Squeeze, Breakout and More Instantly...
OraSure Technologies Inc. Company Name:
OSUR Stock Symbol:
NASDAQ Market:
OraSure Technologies Inc. Website:
2024-07-02 09:00:08 ET Vijay Kumar from Evercore ISI issued a price target of $4.50 for OSUR on 2024-07-02 08:07:00. The adjusted price target was set to $4.50. At the time of the announcement, OSUR was trading at $4.27. OSUR currently trades -49.59% versus its 52 week h...
BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced its support of HIV testing initiatives taking place across the nation in recognition of National HIV Tes...
KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK , ...